Lupin acquires pharma business of Rubamin
Drug maker Lupin Ltd on Thursday said it has acquired the pharmaceutical business of Rubamin group, for an undisclosed amount.
By PTI |
MUMBAI: Drug maker Lupin Ltd on Thursday said it has acquired the pharmaceutical business of Rubamin group, for an undisclosed amount.
The company acquired Rubamin Laboratories Ltd (RLL), the subsidiary of the Rubamin group engaged in manufacture of advanced intermediates for Active Pharmaceutical Ingredients (APIs) under Contract Research and Manufacturing (CRAMS) model, Lupin said informed the Bombay Stock Exchange.
"The acquisition will enable us to step up our strategic initiative in the CRAMS segment," Lupin Chairman Desh Bandhu Gupta said.
Rubamin group is a research driven organisation based in India.
Shares in the company were last trading unchanged at Rs 580 on BSE.
The company acquired Rubamin Laboratories Ltd (RLL), the subsidiary of the Rubamin group engaged in manufacture of advanced intermediates for Active Pharmaceutical Ingredients (APIs) under Contract Research and Manufacturing (CRAMS) model, Lupin said informed the Bombay Stock Exchange.
"The acquisition will enable us to step up our strategic initiative in the CRAMS segment," Lupin Chairman Desh Bandhu Gupta said.
Rubamin group is a research driven organisation based in India.
Shares in the company were last trading unchanged at Rs 580 on BSE.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
